拉帕米辛可降低癌症发生并提高小鼠的存活率,当在非致命的全身辐射后给药时
Anastasia L Sowers1, Sangeeta Gohain1, Elijah F Edmondson2
1Radiation Biology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892.
Radiation research
|August 14, 2024
概括
拉帕米辛是一种mTOR抑制剂,在全身辐射 (TBI) 后,延迟并减少小鼠的辐射诱导癌症. 这种已经获得FDA批准的药物为暴露于辐射的个人提供了潜在的干预措施.
科学领域:
- 辐射瘤学 辐射瘤学
- 预防癌症 预防癌症
- 药理学 药理学是指药理学的学科.
背景情况:
- 由于事故或袭击而暴露于非致命的辐射剂量,会增加癌症的风险.
- 目前还没有安全有效的干预措施来缓解这种辐射诱导的癌症风险.
- 拉帕米辛是一种mTOR抑制剂,具有潜在的治疗应用.
研究的目的:
- 为了测试拉帕米辛的使用是否减少或延迟了辐射诱导的癌症.
- 为了评估在全身辐射 (TBI) 后给出的拉巴素的疗效.
主要方法:
- 雌性C3H/Hen小鼠接受了3 Gy的TBI.
- 在TBI后立即或一个月内,小鼠被食不同度的封装拉巴胺素 (14,40,140毫克/公斤).
- 在整个生命周期中,对老鼠进行了瘤发育和生存的监测.
主要成果:
- 拉巴素通过延迟瘤发病和减少特定瘤的发病率,如肝细胞癌,显著改善了生存率.
- 生存益处是剂量依赖于拉巴胺的度.
- 观察到生存优势,即使拉巴胺的使用延迟了一个月后TBI.
结论:
- 拉帕米辛在减少或延迟辐射诱导的癌症方面显示出有前途.
- mTOR抑制剂拉巴胺可能是非致命性TBI的可行的暴露后干预措施.
- 拉帕米辛的FDA批准支持其在辐射暴露场景中考虑人类使用.
相关概念视频
Replicative Cell Senescence
3.5K
Replicative cell senescence is a property of cells that allows them to divide a finite number of times throughout the organism's lifespan while preventing excessive proliferation. Replicative senescence is associated with the gradual loss of the telomere — short, repetitive DNA sequences found at the end of the chromosomes. Telomeres are bound by a group of proteins to form a protective cap on the ends of chromosomes. Embryonic stem cells express telomerase — an enzyme that adds...
3.5K
mTOR Signaling and Cancer Progression
3.6K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.6K
Mutagenicity and Carcinogenicity
2.0K
Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
2.0K
![Chemical-Induced Skin Carcinogenesis Model Using Dimethylbenz[a]Anthracene and 12-O-Tetradecanoyl Phorbol-13-Acetate DMBA-TPA](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F60445.jpg&w=3840&q=50)

